Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Wyeth |
---|---|
Information provided by: | Wyeth |
ClinicalTrials.gov Identifier: | NCT00037583 |
The primary objectives are a) to establish the maximum tolerated dose (MTD) of gemtuzumab ozogamicin in combination with cytarabine and daunorubicin, and b) to assess the safety of gemtuzumab ozogamicin when given concurrently with cytarabine and daunorubicin.
Condition | Intervention | Phase |
---|---|---|
Acute Myeloid Leukemia |
Drug: Gemtuzumab Ozogamicin |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | A Dose-Ranging Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (Go) Given in Combination With Cytarabine and Daunorubicin in Relapsed or Refractory Patients and in Younger De Novo Patients With Acute Myeloid Leukemia (AML) |
Ages Eligible for Study: | 18 Years to 59 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 0903B1-206 |
Study First Received: | May 17, 2002 |
Last Updated: | May 18, 2006 |
ClinicalTrials.gov Identifier: | NCT00037583 |
Health Authority: | United States: Food and Drug Administration |
Acute Myeloid Leukemia |
Antibodies, Monoclonal Daunorubicin Leukemia Antibodies Acute myelogenous leukemia Leukemia, Myeloid |
Gemtuzumab Leukemia, Myeloid, Acute Acute myelocytic leukemia Cytarabine Immunoglobulins |
Neoplasms Neoplasms by Histologic Type Immunologic Factors Antineoplastic Agents |
Therapeutic Uses Physiological Effects of Drugs Pharmacologic Actions |